Adimmune Corp
TWSE:4142
Intrinsic Value
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. [ Read More ]
The intrinsic value of one Adimmune Corp stock under the Base Case scenario is 23.55 TWD. Compared to the current market price of 28.1 TWD, Adimmune Corp is Overvalued by 16%.
Valuation Backtest
Adimmune Corp
Run backtest to discover the historical profit from buying and selling Adimmune Corp stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Adimmune Corp
Current Assets | 4.7B |
Cash & Short-Term Investments | 2.5B |
Receivables | 1.3B |
Other Current Assets | 921.2m |
Non-Current Assets | 4.8B |
Long-Term Investments | 133.2m |
PP&E | 4B |
Intangibles | 70.5m |
Other Non-Current Assets | 605m |
Current Liabilities | 1.8B |
Accounts Payable | 42.4m |
Short-Term Debt | 540m |
Other Current Liabilities | 1.2B |
Non-Current Liabilities | 2.2B |
Long-Term Debt | 1.9B |
Other Non-Current Liabilities | 305m |
Earnings Waterfall
Adimmune Corp
Revenue
|
1.8B
TWD
|
Cost of Revenue
|
-1.4B
TWD
|
Gross Profit
|
410.9m
TWD
|
Operating Expenses
|
-1.1B
TWD
|
Operating Income
|
-722.7m
TWD
|
Other Expenses
|
82.9m
TWD
|
Net Income
|
-639.9m
TWD
|
Free Cash Flow Analysis
Adimmune Corp
Profitability Score
Profitability Due Diligence
Adimmune Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Adimmune Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Adimmune Corp's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Adimmune Corp's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Adimmune Corp
According to Wall Street analysts, the average 1-year price target for Adimmune Corp is 35 TWD .
Shareholder Return
Price
Adimmune Corp
Average Annual Return | 26.89% |
Standard Deviation of Annual Returns | 63.43% |
Max Drawdown | -67% |
Market Capitalization | 11.8B TWD |
Shares Outstanding | 421 508 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
Contact
IPO
Employees
Officers
The intrinsic value of one Adimmune Corp stock under the Base Case scenario is 23.55 TWD.
Compared to the current market price of 28.1 TWD, Adimmune Corp is Overvalued by 16%.